AstraZeneca plc (AZN) Stake Increased by Bank of Hawaii

Bank of Hawaii grew its holdings in AstraZeneca plc (NYSE:AZN) by 2.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 97,709 shares of the company’s stock after buying an additional 2,134 shares during the quarter. Bank of Hawaii’s holdings in AstraZeneca were worth $3,391,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Fisher Asset Management LLC lifted its holdings in shares of AstraZeneca by 2.7% in the 4th quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock valued at $413,531,000 after buying an additional 315,759 shares during the period. Wells Fargo & Company MN raised its holdings in AstraZeneca by 7.6% during the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after purchasing an additional 310,389 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in AstraZeneca by 7.1% during the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock worth $102,643,000 after purchasing an additional 199,519 shares during the last quarter. Capital Bank & Trust Co raised its holdings in AstraZeneca by 2.1% during the third quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock worth $92,499,000 after purchasing an additional 57,353 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in AstraZeneca by 18.3% during the third quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock worth $86,695,000 after purchasing an additional 395,699 shares during the last quarter. 14.91% of the stock is owned by institutional investors and hedge funds.

AstraZeneca plc (AZN) opened at $33.69 on Friday. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $84,700.00, a price-to-earnings ratio of 28.55, a price-to-earnings-growth ratio of 2.04 and a beta of 0.74. AstraZeneca plc has a 1 year low of $28.43 and a 1 year high of $36.70.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.86. The company had revenue of $5.78 billion during the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. AstraZeneca’s revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.21 earnings per share. sell-side analysts forecast that AstraZeneca plc will post 1.67 EPS for the current fiscal year.

The business also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be given a dividend of $0.95 per share. This represents a yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. AstraZeneca’s payout ratio is 116.10%.

Several equities analysts recently issued reports on AZN shares. JPMorgan Chase & Co. raised AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. BMO Capital Markets set a $38.00 price objective on AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, January 10th. Leerink Swann reaffirmed a “market perform” rating and set a $36.00 price objective (up from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Finally, Sanford C. Bernstein lifted their price objective on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $36.26.

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Stake Increased by Bank of Hawaii” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/23/astrazeneca-plc-azn-stake-increased-by-bank-of-hawaii.html.

AstraZeneca Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply